An antibacterial nanotransdermal delivery system and its preparation method
By using a transdermal nanoparticle delivery system that loads black phosphorus quantum dots and vancomycin onto liposomes modified with macrophage membranes, combined with photothermal therapy, the problems of low drug loading, high nephrotoxicity, and poor targeting in existing antibiotic treatments for superbugs have been solved, achieving highly efficient bacterial killing and reduced drug side effects.
Patent Information
- Application Number
- CN202310114922.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-15
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-02-15
AI Technical Summary
Existing antibiotic treatments for superbugs such as MRSA suffer from problems such as low drug loading, high nephrotoxicity, poor targeting, and drug resistance, making it difficult to effectively eradicate bacteria hidden in macrophages.
A nano-transdermal delivery system using liposomes modified with macrophage membranes loaded with black phosphorus quantum dots and vancomycin delivers drugs via microneedles, combined with photothermal therapy, to achieve precise targeted drug delivery and synergistic antibacterial effects.
It significantly improved antibacterial ability, reduced the dosage of vancomycin, decreased drug side effects, enhanced drug targeting and circulation time, avoided damage to other organs, and achieved highly efficient bacterial eradication.
Smart Images

Figure CN116019785B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a targeted drug delivery system and its preparation method, and more particularly to a microneedle-loaded biomimetic nanocomposite antibacterial targeted drug delivery system and its preparation method. Background Technology
[0002] Bacterial infections contribute to high mortality and morbidity rates globally. More than 700,000 people die annually worldwide from drug-resistant bacterial infections due to ineffective treatment, posing a major threat to public health. In the early 20th century, antibiotics were invented to combat bacterial microorganisms. However, the overuse of antibiotics and the presence of bacterial biofilms in recent years have led to the emergence of numerous drug-resistant bacteria, forming difficult-to-treat "superbugs," such as methicillin-resistant Staphylococcus aureus (MRSA). These bacteria exhibit resistance to antibiotics, easily causing severe systemic infectious diseases such as sepsis in critically ill patients, leading to death. Many intracellular bacterial pathogens multiply in the shelter provided by macrophages. After phagocytosis by macrophages, bacteria initially reside in membrane-bound phagosomes, which fuse with lysosomes, where they are typically killed by reactive oxygen species, lysozymes, and cationic antimicrobial peptides. However, superbugs can remain dormant in the low pH environment of phagosomes and persist within them for extended periods. In conclusion, eradicating bacteria hiding within macrophages is crucial for the long-term success of antibiotic therapy. Therefore, treatment of superbugs is urgently needed. MRSA, as a typical superbug and a Gram-positive bacterium, is quite representative. It is a major factor causing wound or systemic infections after surgery in critically ill patients; therefore, MRSA is a significant area of research focus.
[0003] Vancomycin is a common drug for treating MRSA. It is a glycopeptide antibiotic with a narrow antibacterial spectrum. It works by inhibiting bacterial cell wall synthesis and altering bacterial cell membrane permeability, thus hindering bacterial RNA synthesis and leading to bacterial death. However, it carries certain risks during treatment due to its significant ototoxicity and nephrotoxicity, and the potential for adverse reactions such as phlebitis and "red man syndrome" when administered intravenously. Furthermore, because vancomycin is a water-soluble drug, the encapsulation efficiency of common vancomycin liposomes is very low, only 8%, making it crucial to address the issue of increasing the drug loading capacity of vancomycin. Summary of the Invention
[0004] Purpose of the invention: The purpose of this invention is to provide a nano-transdermal delivery system with increased safety and strong antibacterial effect, and also to provide a method for preparing the above-mentioned drug delivery system.
[0005] Technical solution: The antibacterial nano-transdermal delivery system of the present invention is a transdermal delivery system formed by a cell membrane-coated phototherapy agent and vancomycin forming a lipid carrier, and loading the lipid carrier into microneedles, wherein the mass ratio of the phototherapy agent and vancomycin is 0.5:1-4:1.
[0006] Preferably, the phototherapy agent is black phosphorus quantum dots, and the cell membrane is a macrophage membrane.
[0007] The method for preparing the above delivery system includes the following steps:
[0008] (1) Phospholipids and cholesterol were mixed and dissolved in an organic solvent and evaporated under reduced pressure to obtain a thin film. A aqueous dispersion of black phosphorus quantum dots and vancomycin aqueous solution were added and hydrated until complete. The film was then ultrasonically dispersed in an ice bath to obtain a nano-suspension containing opalescence. After filtration, the liposome drug-carrying core was obtained.
[0009] (2) The drug-carrying core of the liposome is mixed with the macrophage membrane, sonicated and physically extruded through a polycarbonate membrane, and the resulting liquid is centrifuged to remove excess free membrane to obtain the lipid carrier.
[0010] (3) Prepare an aqueous solution of lipid carrier, dissolve polyvinylpyrrolidone in the aqueous solution of lipid carrier, inject it into a microneedle mold to obtain microneedle tips, then add base liquid, dry and demold to obtain antibacterial nanotransdermal delivery system.
[0011] Preferably, in step (1), the mass ratio of the phospholipids, cholesterol, black phosphorus quantum dots and vancomycin is 24:8:2:1 to 24:8:8:4.
[0012] Preferably, in step (1), the concentration of the aqueous dispersion of black phosphorus quantum dots is 10-100 μg / ml, and the concentration of vancomycin aqueous solution is 50-500 μg / ml.
[0013] Preferably, in step (2), the mass ratio of the drug-loaded core to the macrophage membrane is 0.5:1-2:1.
[0014] Preferably, in step (3), the concentration of the aqueous solution of the lipid carrier is 50 mg / mL.
[0015] Preferably, the preparation of the liposome drug-carrying core involves dissolving phospholipids and cholesterol in an organic solvent, rotary evaporating under reduced pressure in a 40°C water bath to obtain a thin film, vacuum drying overnight to remove excess organic solvent, then adding an aqueous dispersion of black phosphorus quantum dots (BPQD) and an aqueous solution of vancomycin in a 40°C water bath until fully hydrated, ultrasonically dispersing in an ice bath to obtain a luminescent nano-suspension, and filtering the suspension through a microporous membrane.
[0016] Preferably, the preparation of the macrophage membrane specifically involves adjusting the macrophage cell density to 2.5*10 using 4℃™ buffer. 7 / mL, the cell membrane was sonicated under ice bath and mixed with 1M sucrose solution to make a cell suspension with a sucrose concentration of 0.25M; the supernatant was collected by centrifugation at 2000g for 10min at 4℃, and then centrifuged at 3000g for 30min. The supernatant was discarded, and the cell was resuspended in TM buffer containing 0.25M sucrose at 4℃. The cell was centrifuged again at 3000g for 30min. The precipitate was collected and lyophilized to obtain the cell suspension.
[0017] Invention Principle: This invention utilizes macrophage membrane-modified liposomes as carriers for antibacterial drug delivery. The macrophage membrane targets Gram-positive bacteria, precisely delivering the drug to the infection site. Simultaneously, nanotechnology is used to deliver antibiotics or phototherapy agents to the infection site, avoiding biotoxicity to other organs. Furthermore, the photothermal antibacterial effect provided by the photothermal agent does not induce drug resistance. In addition, the photodynamic therapy (PDT) generated by the optical materials produces reactive oxygen species (ROS), which promotes lipid peroxidation in bacteria, leading to increased cell membrane permeability and bacterial lysis and death. Simultaneously, the photothermal effect (PTT) from the photothermal agent enables bacteria to produce more ATP to maintain normal metabolic activity in harsh environments. Black phosphorus is a highly biocompatible photosensitizer that produces excellent PDT and PTT effects under near-infrared excitation at 808 nm. Moreover, it can be metabolized into phosphate in vivo and has no toxic side effects on humans. Furthermore, black phosphorus quantum dots (BPQDs) possess high specific surface area and high photothermal conversion efficiency, making them suitable not only as photosensitizers but also as carriers to increase drug loading. Under near-infrared excitation at specific wavelengths, they can induce the PTT effect, thus enabling their use in bacterial therapy. Bacteria consume more ATP at higher temperatures to maintain their metabolic levels. In the PTT effect, BP can generate singlet oxygen (ROS), promoting lipid peroxidation in bacterial membranes, increasing membrane permeability, and ultimately leading to bacterial death. Using biomimetic membranes to encapsulate liposomes not only inherits the advantages of macrophages, achieving long-circulation function, but also allows for precise targeting to the infection site, avoiding burden on other organs. Simultaneously, since intravenous administration easily causes hepatic and renal accumulation, local administration via microneedles not only avoids nephrotoxicity but also improves patient compliance.
[0018] This invention utilizes liposomes to load antibacterial drugs into a drug-carrying core and constructs a biomimetic outer shell using macrophage membranes, loading the drug onto microneedles to create a microneedle-loaded antibacterial biomimetic nano-targeted drug delivery system. Thermosensitive liposomes prepared by combining black phosphorus quantum dots and vancomycin can be used in conjunction with chemotherapy and phototherapy to achieve synergistic antibacterial effects. However, due to the poor targeting of liposomes in vivo, drug accumulation in different organs can easily occur, causing damage to the liver and kidneys. Therefore, this invention uses macrophage membranes to encapsulate liposomes, leveraging the characteristics of macrophages such as long circulation and immune escape, as well as the presence of TLR2 and TLR6 targets on the macrophage membrane, to precisely deliver liposomes to bacteria and avoid damage to other organs. Furthermore, the key to this invention is the use of co-extrusion to determine the correct number of extrusions and the mass ratio of phospholipids to cell membranes, achieving the highest liposome encapsulation efficiency with optimal cell membrane mass.
[0019] In this invention, the ratio of BPQD to VA is crucial for stabilizing the liposome core. Since BPQD is negatively charged and VA is positively charged, a neutral or negatively charged drug-loaded core in cationic liposomes contributes to structural stability. When the BPQD:VA ratio is 2:1, the potential is weakly negative. Changing this ratio leads to potential instability, which in turn affects and reduces the encapsulation efficiency of the liposomes.
[0020] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: (1) The liposomes modified by macrophage membrane load water-soluble BPQD and VA to form VB@ML lipid carrier, which can realize the precise targeted delivery of antibacterial drugs and improve their efficacy. The antibacterial ability is nearly 10 times higher than that of each antibacterial drug used alone. In addition, the system can improve the stability of BPQD and reduce the amount of VA required, from 2μg / mL to 1μg / mL, which reduces the amount of drug by 50%; (2) The nano-drug delivery system enters the body through microneedle administration and reaches the site of infection. Under the action of macrophage membrane, it accumulates at the site of infection. BPQD local exothermics under 808nm laser irradiation promotes the complete release of drugs in biomimetic nanoparticles. Attached Figure Description
[0021] Figure 1 Figure A shows the characterization results of VB@Lip nanoparticles in Example 1, where Figure A is the particle size diagram and transmission electron microscope (TEM) image of VB@Lip nanoparticles, and Figure B is the TEM image of BPQD.
[0022] Figure 2 Figure A shows the characterization results of the VB@ML nanocomposite in Example 2, where Figure A is a transmission electron microscope image of VB@ML and Figure B is an SDS-PAGE electrophoresis image of VB@ML.
[0023] Figure 3The flow cytometry colocalization map of the VB@ML nanocomposite in Example 2 is shown below.
[0024] Figure 4 The particle size distribution and transmission electron microscopy (TEM) image of the VB@ML nanocomposite in Example 2 are shown.
[0025] Figure 5 This is a photothermal imaging image of the VB@ML nanocomposite in Example 2;
[0026] Figure 6 Figure A shows the stability results of the VB@ML nanocomposite in Example 2. Figure B shows the changes in particle size and PDI of the aqueous dispersion of VB@ML nanocomposite during the stability study, and Figure B shows the changes in particle size and PDI of the 10% fetal bovine serum dispersion during the stability study.
[0027] Figure 7 This is a stereomicroscopic image of VB@ML MN in Example 2;
[0028] Figure 8 This is a diagram illustrating the dissolution process of VB@ML MN in Example 2;
[0029] Figure 9 The cytotoxicity of the VB@ML nanocomposite in Example 3 is investigated. Figure A shows the cytotoxicity of the VB@ML nanocomposite to HUVECs, and Figure B shows the cytotoxicity of the VB@ML nanocomposite to L929 cells.
[0030] Figure 10 This is a graph showing the inhibition of MRSA growth by the VB@ML nanocomposite in Example 4.
[0031] Figure 11 This is an investigation into the effect of VB@ML on the dispersion of MRSA biofilm in Example 5;
[0032] Figure 12 The distribution of fluorescently labeled VB@ML MN in infected mice and in vitro organs in Example 6 is shown.
[0033] Figure 13 The image shows the H&E staining results of mouse heart, liver, spleen, lung, and kidney tissue sections in the in vivo safety evaluation of VB@ML MN in Example 7.
[0034] Figure 14 This is a graph showing the changes in body weight of mice during treatment with different formulation groups in Example 8;
[0035] Figure 15 The image shows the results of H&E staining and Masson staining of mouse skin in the evaluation of in vivo antibacterial wound healing by VB@ML MN in Example 8. Detailed Implementation
[0036] The technical solution of the present invention will be further described below with reference to the accompanying drawings.
[0037] Example 1
[0038] Preparation and characterization of VB@Lip nanoparticles
[0039] (1) Preparation of VB@Lip nanoparticles
[0040] Accurately weigh 0.5 mg DOTAP, 2.5 mg DOPE, and 1 mg cholesterol and dissolve them in 5 mL of methanol. After complete dissolution, transfer the solution to a brown gaiwan flask and rotary evaporate under reduced pressure in a 40°C water bath for 15 min. After the solvent has completely evaporated and a uniform lipid film has formed at the bottom of the flask, measure 10 mL of 100 μg / mL BPQD aqueous dispersion and weigh 0.5 mg VA and dissolve it in the dispersion. Allow the mixture to react for a period of time to allow it to fully combine, and purge with nitrogen for protection during the reaction. Then, add this mixture to the flask and hydrate at 40°C for 30 min. After the lipid film is fully hydrated, sonicate the resulting lipid suspension in an ice bath for 15 min at 200 W with an on-time of 2 s and a off-time of 2 s to obtain lipid nanoparticles. Finally, filter the nanoparticles sequentially through 0.45 μm and 0.22 μm aqueous microporous membranes to obtain an aqueous solution of VB@Lip nanoparticles.
[0041] (2) Characterization of VB@Lip nanoparticles
[0042] The particle size of VB@Lip nanoparticles in aqueous solution was measured using dynamic light scattering (DLS), and the results are shown in the attached figure. Figure 1 As shown in Figure A, the average particle size of the nanoparticles is 78.4 ± 1.3 nm. The structures of BPQD and VB@Lip nanoparticle aqueous solutions were observed by transmission electron microscopy (TEM), and the results are shown in the attached figure. Figure 1 As shown, the actual nanoparticle size is close to the detected particle size, and the structure of BPQD encapsulated in liposomes is clearly visible, indicating that VB@Lip nanoparticles were successfully prepared.
[0043] Example 2
[0044] Preparation, characterization and property study of VB@ML nanocomposites
[0045] (1) Cultivation of RAW 264.7
[0046] RAW264.7 macrophages (passage 5 or less) were selected and seeded into cell culture flasks. They were cultured in DMEM medium containing 10% bovine serum emtansine peptide and placed in an incubator at 37°C, 5% CO2, and 95% humidity. When the cells reached a suitable density, they were digested with 0.25% trypsin at room temperature for 1 min. Digestion was stopped when the cells became rounded, and the adherent cells were gently detached by pipetting. The cell suspension was collected and centrifuged at 1000 rpm for 5 min to pellet the cells. The supernatant was discarded, and the cells were resuspended in fresh complete culture medium. Finally, the cells were seeded into cell culture flasks at a suitable density and cultured as described above.
[0047] (2) Extraction of macrophage membrane (Ma)
[0048] After centrifugation at 1000 rpm for 5 min, the supernatant was discarded to obtain macrophages. The cell density was adjusted to 2.5*10^6 cells / min using 4℃™ buffer. 7 Cell membranes were sonicated at 80W on ice in a homogenate bath. 1M sucrose solution was added to the homogenate to prepare a 0.25M sucrose suspension. The suspension was centrifuged at 2000g for 10 min at 4°C, and the supernatant was collected. Then, the suspension was centrifuged at 3000g for 30 min, and the supernatant was discarded. The suspension was resuspended in TM buffer containing 0.25M sucrose at 4°C, and centrifuged again at 3000g for 30 min. The precipitate was collected as the macrophage membrane.
[0049] (3) Characterization of Ma
[0050] The structure of the macrophage membrane aqueous dispersion was observed by transmission electron microscopy (TEM), and the results are shown in the attached figure. Figure 2 As shown in Figure A; SDS-PAGE electrophoresis was used to analyze the total protein profile of Ma, and the results are attached. Figure 2 As shown in Figure B, the Ma and VB@ML groups showed consistent protein bands. The concentrations of Ma's characteristic proteins TLR2 and TLR6 did not differ significantly between the two groups, indicating that Ma successfully coated the liposome surface without affecting its structural properties and biological activity.
[0051] (4) Preparation of VB@ML nanocomposites
[0052] The freeze-dried Ma was dissolved in an aqueous solution, sonicated at 80W for 5 min, and then the liposomes were mixed with Ma. The mixture was sonicated again at 80W for 5 min and then physically extruded through a 400nm polycarbonate membrane to form an antibacterial targeted biomimetic nanocomposite VB@ML. The free Ma was then removed by centrifugation at 4℃ and 6000g for 5 min.
[0053] (5) Characterization of VB@ML nanocomposites
[0054] Fluorescence co-localization assay: DiI and C6 co-labeled VB@ML nanocomposites (DC@ML) were prepared according to the optimal formulation process, replacing Ma with Ma-DiI and C6 with C6. Flow cytometry was used to quantify the encapsulated liposomes. The results are shown in the attached figure. Figure 3 As shown, flow cytometry revealed that both fluorescent markers in the fluorescently labeled DC@ML exhibited high fluorescence intensity, demonstrating that the macrophage membrane was successfully encapsulated on the liposomes.
[0055] The particle size of the VB@ML nanocomposite aqueous solution was measured using dynamic light scattering (DLS), and the results are shown in the attached figure. Figure 4 As shown, the average particle size of the nanocomposite is 103.4 ± 0.6 nm; the structure of the VB@ML nanocomposite aqueous solution was observed by transmission electron microscopy (TEM), and the results are shown in the attached figure. Figure 4 As shown, the actual size of the nanocomposite is similar to the detected particle size, and it is larger in size and more rounded in shape than VB@ML nanoparticles. The outermost layer has a distinct shell structure, indicating that Ma was successfully modified on the liposome surface and the VB@ML nanocomposite was successfully prepared.
[0056] (6) Properties of VB@ML nanocomposites
[0057] To investigate the photothermal conversion capability of the VB@ML nanocomposite, four groups were set up: PBS, BPQD, BPQD@Lip, and BPQD@ML. Sample solutions were measured and placed in EP tubes, and then analyzed using an 808nm laser emitter (1.5W / cm²). 2 The tube was irradiated for 10 minutes, and the thermal radiation images of the EP tube and the temperature change of the dispersion were recorded using a thermal imager during the irradiation process. The results are attached. Figure 5 As shown, liposome encapsulation and macrophage membrane modification had almost no effect on the photothermal properties of BPQD, and there was no significant difference in photothermal conversion capacity compared with BPQD aqueous dispersion.
[0058] The particle size stability of the VB@ML nanocomposite aqueous dispersion during the standing process was investigated, and the results are shown in the attached figure. Figure 6 As shown in Figure A: The particle size stability of the VB@ML nanocomposite was investigated using a culture medium containing 10% fetal bovine serum to simulate the in vivo environment. The results are shown in the attached figure. Figure 6 As shown in Figure B, the particle size and PDI of the nanocomposite fluctuated with the extension of the standing time, and the particle size change was all <20%, and the PDI was all <0.3, indicating that the aqueous dispersion of the nanocomposite and its in vitro serum had good stability.
[0059] Preparation, characterization and property study of VB@ML MN delivery system
[0060] (1) Preparation of VB@ML MN delivery system
[0061] After freeze-drying VB@ML, weigh 10 mg of the freeze-dried product, dissolve it in 500 μL of PBS, and add PVP(K30) to make the concentration of PVP(K30) 15% (w / v). Take 200 μL of the mixed solution and add it dropwise into a 15*15 microneedle mold, then vacuum dry for 1.5 h. Prepare a 15% (w / v) PVA-1788 aqueous solution, fill the microneedle mold, and place it in an oven to dry overnight. Then, demold and remove VB@ML MN.
[0062] (2) Characterization of the VB@ML MN delivery system
[0063] The length of the needle tip was observed using a stereomicroscope. The microneedle was placed under the stereomicroscope, and its shape was photographed using a bright field light source. The actual length of the needle tip was measured. The results are shown in the attached figure. Figure 8 , scale bar = 200μm.
[0064] (1) Study on the properties of the VB@ML MN delivery system
[0065] The tip of VB@ML MN was immersed in PBS, and removed at 1, 5, 10, 30, 60, and 120 min, and then photographed under a bright-field light source in a stereo microscope. The results are shown in the attached figure. Figure 9 The scale bar was 500 μm. The results showed that the microneedle was soluble, with nearly 80% of the tip dissolved in 3 minutes and completely dissolved in 5 minutes, indicating that the microneedle was a rapidly dissolving microneedle.
[0066] Example 3
[0067] In vitro toxicity study of VB@ML nanocomposites for HUVEC and L929
[0068] HUVEC and L929 cells in the logarithmic growth phase and in good growth condition were seeded and inoculated at 8 × 10⁻⁶ cells per cell line. 3Cells were seeded at a density of 100 μL / well in 96-well plates, with 3 replicates. Each well contained 100 μL of complete DMEM medium and was incubated at 37°C in a 5% CO2 incubator. After cell attachment, cells were cultured in DMEM basal medium containing VB@ML for 24 h. The working concentrations of VB@ML were 0.3125, 0.625, 1.25, 2.5, 5, 10, 20, 25, and 50 μg / mL (final VA concentration determined). A control group (no VB@ML) and a blank group (PBS only) were established. The culture medium was then discarded, and the cells were washed with PBS buffer. 120 μL of serum-free medium containing 20 μL of 5 mg / mL MTT solution was added to each well, and the cells were incubated at 37°C in a 5% CO2 incubator for 4–6 h. The culture medium was then discarded, and 150 μL of dimethyl sulfoxide was added to each well. The absorbance of each well was measured at 490 nm using a microplate reader, and cell viability was calculated using the following formula. Results are attached. Figure 10 As shown, attached Figure 9 A represents the in vitro toxicity of the formulation to HUVECs, attached... Figure 9 B represents the in vitro toxicity of the formulation to L929. This indicates that the safety of the nanocomposite carrier is guaranteed.
[0069] Cell viability = (A Sample -A PBS ) / (A control- A PBS )×100%
[0070] A Sample —Absorbance of the drug-treated cell group
[0071] A PBS —Absorbance of PBS solution
[0072] A control —Absorbance of untreated cell groups
[0073] Example 4
[0074] Study on the inhibitory effect of VB@ML nanocomposite on the growth curve of bacterial MRSA
[0075] Prepare LB medium, culture MRSA to the logarithmic growth phase, and then dilute to 10⁻⁶. 7 CFU / mL. PBS, VA (1 μg / mL), BPQD (10 μg / mL), and photothermal groups BPQD (10 μg / mL), BPQD-VA (10+1 μg / mL), VB@Lip (10+1 μg / mL), and VB@ML (10+1 μg / mL) were added respectively and heated under 808 nm laser conditions at 1.5 W / cm². 2 Irradiate with high power for 5 minutes, and measure OD every hour using an ELISA reader. 600The values were measured over a total of 12 hours. Results are attached. Figure 10 As shown, VA or BPQD alone do not provide a good antibacterial effect. However, the BPQD(+) group exhibits a strong bactericidal effect, reducing bacterial survival rate by approximately 20%. Combining BPQD and VA with light exposure not only reduces the dosage but also achieves nearly 50% antibacterial efficacy. After administration of VB@Lip and VB@ML separately with light exposure, the bacterial survival rate was similar, only around 15%, significantly improving the antibacterial effect. This indicates that VB@ML has a good bactericidal effect and can reduce the dosage, thus avoiding some of the toxic side effects caused by VA.
[0076] Example 5
[0077] Study on the effect of VB@ML nanocomposite on bacterial MRSA biofilm dispersion
[0078] Add 990 μL of fresh LB medium to each well of a 24-well plate, then add 10 μL of LMRSA bacterial suspension (1×10⁻⁶) to each well. 7 The plate was incubated at 37°C for 48 hours, with the culture medium changed every 24 hours to allow biofilm formation. After 48 hours, the supernatant was carefully discarded and the wells were washed with PBS to remove the culture medium and unfixed bacteria. Finally, a biofilm formed at the bottom of each well. 0.2 mL of different concentrations of sample diluted with LB medium was added to each well containing the biofilm. Wells containing LB medium served as controls. After incubation for 24 hours, the supernatant was removed, and the remaining biofilm was washed with PBS. 0.5% crystal violet staining solution was added to each well for 0.5 hours. After staining, the wells were washed with PBS, and the stained biofilm at the bottom of the plate was photographed. Anhydrous ethanol was then added to each well to dissolve the crystal violet at the bottom. The absorbance (OD590) at 590 nm was measured using a microplate reader to assess the residual biofilm. Results are attached. Figure 11 The results showed that the VB@ML group exhibited the best biofilm dispersion effect, with almost no biofilm remaining at the bottom of the wells, a significant difference compared to the PBS group. Meanwhile, the BPQD(+) group showed a significant biofilm dispersion effect compared to the unilluminated group, indicating that PDT can promote bacterial death.
[0079] Example 6
[0080] Distribution of the fluorescently labeled VB@ML system in vivo and in vitro organ tissues of mice with bacterial skin abscesses.
[0081] A mouse skin wound model was constructed, and mice were divided into three groups: DiR@Lip, DiR@ML, and DiR@ML MN, which were administered via tail vein and microneedle, respectively. The distribution of DiR fluorescence emission within the mice was observed using an in vivo imaging system at 0, 2, 8, 12, 24, and 48 hours post-administration. Mice were sacrificed after 48 hours, and heart, liver, spleen, lung, and kidney tissues were dissected and extracted. The indistinct DiR fluorescence emission within the isolated tissues was then observed using an in vivo imaging system. Results are attached. Figure 12 As shown, in the DiR@Lip group, the cumulative fluorescence level at the infection site reached its peak after 24 hours, but decreased after 48 hours, indicating that the liposomes degraded in vivo and could not accumulate. However, the fluorescence intensity in the DiR@ML group was higher than that in the DiR@Lip group at 24 hours, and the fluorescence intensity continued to increase after 48 hours, indicating that DiR@ML has better accumulation capacity and targeting in mice. In the DiR@ML MN group, the fluorescence intensity was stronger than that of intravenously injected mice in the first 24 hours, and the fluorescence intensity decreased significantly after 48 hours. In ex vivo organs, the fluorescence intensity of DiR@Lip and DiR@ML was almost the same and strong, while the mouse organs of DiR@ML MN showed no fluorescence, indicating that DiR@ML MN has the strongest targeting in mice and almost no effect on in vivo organs, demonstrating high biosafety and targeting.
[0082] Example 7
[0083] In vivo safety evaluation of the VB@ML MN system
[0084] Healthy female ICR mice were randomly divided into two groups: one group received PBS via tail vein injection, and the other group received VB@MLMN. After treatment, the mice were sacrificed, and the heart, liver, spleen, lungs, and kidneys were dissected and fixed in 4% paraformaldehyde. After fixation, the tissues were embedded in paraffin, and finally, sections were stained with Hematoxylin and eosin (H&E) for observation. The H&E staining results are attached. Figure 13 As shown in the scale bar (200μm), compared with the PBS control group, no pathological changes such as lesions, necrosis, or morphological abnormalities were found in any tissue of the VB@ML MN administration group selected from normal healthy female ICR mice. Their histological morphology was normal, indicating that the VB@ML MN system has good in vivo safety.
[0085] Example 8
[0086] Evaluation of the in vivo antibacterial effect of the VB@ML MN system
[0087] Normal female ICR mice were randomly divided into five groups: PBS, VA, VB@Lip(+), VB@ML(+), and VB@ML MN(+). A circular wound was created on the back of each mouse, and 10 mg of VB@Lip was applied to each group. 9A wound infection model was established after one day using CFU / mL MRSA. Different groups were administered the drug via tail vein and microneedle, respectively. The light-treated group received 808nm laser at 1.5W / cm². 2 The mice were irradiated for 5 minutes under the specified conditions for seven days. Their weight was recorded daily, and skin samples from the wound sites were collected for H&E and Masson staining. Results are attached. Figure 14 The results showed that the body weight of mice in the PBS group decreased, while the body weight of mice in the VB@Lip, VB@ML, and VB@ML MN groups all showed an increasing trend. This not only indicates the good biosafety of the formulation but also demonstrates that the therapeutic effect of the formulation is significantly improved compared to the PBS group. H&E staining and Masson staining are shown in the attached figure. Figure 15 As shown, the epidermis of the skin in the PBS group was severely damaged and inflammatory factors increased significantly, while the epidermis of the VB@ML MN group grew out completely, with the fewest inflammatory factors and hair follicles growing out gradually, proving that the VB@ML MN preparation has excellent antibacterial effect.
[0088] Example 9
[0089] Preparation of the liposome drug delivery core VB@Lip: Compared with Example 1, the ratio of BPQD and VA was changed:
[0090] BPQD addition amount Amount of VA added The ratio of BPQD to VA VB@Lip-1 4 0.5 8:1 VB@Lip-2 2 0.5 4:1 VB@Lip-3 1 0.5 2:1 VB@Lip-4 0.25 0.5 0.5:1 VB@Lip-5 0.125 0.5 0.25:1
[0091] When the BPQD:VA ratio was 8:1 and 0.25:1, the potential was too negative or too positive and unstable, resulting in very low encapsulation efficiency of the liposomes. When the BPQD addition was 2, 1, and 0.25, the potentials of the mixture were -17.5 mV, 2.47 mV, and 3.8 mV, respectively, which were within a reasonable range and the potentials were stable. Using a BPQD:VA ratio of 2:1 resulted in a moderate potential and a higher drug encapsulation efficiency.
[0092] The microneedle-loaded biomimetic nanocomposite antibacterial targeted drug delivery system of the present invention greatly improves the drug's targeting ability through its microneedle delivery method; at the same time, the construction of the biomimetic nanocomposite not only improves the drug's targeting but also enhances its biocompatibility in vivo; furthermore, the stability of BPQD is improved, and the drug's permeation and release are promoted under laser irradiation, and the PDT / PTT effect can induce bacterial death.
[0093] The constructed VB@ML MN first utilizes cationic liposomes, which have a strong electrostatic adsorption capacity for bacteria in acidic environments. Secondly, it encapsulates the cationic liposomes with a macrophage membrane, which not only reduces the potential of the formulation and avoids hemolytic effects, but also inherits the characteristics of macrophages, possessing specific bacterial recognition capabilities and chemotactic attraction to inflammatory sites for precise targeting. Furthermore, it utilizes the drug delivery characteristics of microneedles to deliver drugs more precisely to the dermis, overcoming the barrier of the stratum corneum, while avoiding stimulation of nerves and blood vessels, thus improving drug compliance. This invention uses liposomes and macrophage membranes as carriers, combining VA chemotherapy with BPQD phototherapy, and by delivering drugs through the macrophage membrane, it avoids the adaptation and clearance of the reticuloendothelial system, achieving immune escape and increasing the drug's circulation time in the body.
Claims
1. An antibacterial nanotransdermal delivery system, characterized in that, The drug delivery system is formed by encapsulating a phototherapy agent and vancomycin in a cell membrane and loading the lipid carrier into a microneedle; the cell membrane is a macrophage membrane; the phototherapy agent is black phosphorus quantum dots, and the ratio of black phosphorus quantum dots to vancomycin is 4:1, 2:1 or 0.5:
1.
2. The method for preparing the delivery system according to claim 1, characterized in that, Includes the following steps: (1) Phospholipids and cholesterol were mixed and dissolved in an organic solvent and evaporated under reduced pressure to obtain a thin film. A aqueous dispersion of black phosphorus quantum dots and vancomycin aqueous solution were added and hydrated until complete. The film was then ultrasonically dispersed in an ice bath to obtain a nano-suspension containing opalescence. After filtration, the liposome drug-carrying core was obtained. (2) The drug-carrying core of the liposome is mixed with the macrophage membrane, sonicated and co-extruded, and the excess free membrane is removed by centrifugation to obtain the lipid carrier; (3) Prepare an aqueous solution of lipid carrier, dissolve polyvinylpyrrolidone in the aqueous solution of lipid carrier, inject it into a microneedle mold to obtain microneedle tips, then add base liquid, dry and demold to obtain antibacterial nanotransdermal delivery system.
3. The preparation method according to claim 2, characterized in that, In step (1), the concentration of the aqueous dispersion of black phosphorus quantum dots is 10~100μg / ml.
4. The preparation method according to claim 2, characterized in that, In step (1), the concentration of the vancomycin aqueous solution is 50-500 μg / ml.
5. The preparation method according to claim 2, characterized in that, In step (2), the mass ratio of the drug-carrying core of the liposome to the macrophage membrane is 0.5-2:
1.
6. The preparation method according to claim 2, characterized in that, In step (3), the concentration of the lipid carrier aqueous solution is 50 mg / mL.
Citation Information
Patent Citations
Preparation and application of cytomembrane biomimic lipoprotein targeted nanometer drug delivery system
CN108837154A
Vancomycin-modified black phosphorus quantum dot antibacterial agent and preparation method and application thereof
CN111840322A
